Evaluation of a Dietary Supplementation Combining Proteins and Pomegranate Extracts in Older People (Delicens2021)

Université Catholique de Louvain

Status

Completed

Conditions

Healthy Aging

Treatments

Dietary Supplement: Dietary Supplement

Other: Placebo of the dietary supplement

Study type

Interventional

Funder types

Other

Identifiers

NCT05527249

Delicens2021

Details and patient eligibility

About

The objective of this safety study is to evaluate the safety of a combination of proteins and pomegranate extracts in healthy subjects aged 65 years or more after 21 days of supplementation.

Full description

The aim of the Delicen's project is to find an effective solution to avoid undernutrition in the elderly by proposing an assortment of food products for people who are undernourished or at risk of undernutrition. These products will be enriched with proteins and pomegranate extracts. Before to realize the impact study to test products enriched with proteins and pomegranate extracts, a safety study will be carried out.

The objective of this safety study (double-blind randomized clinical trial) is to evaluate the safety of a combination of proteins and pomegranate extracts in healthy subjects aged 65 years or more in comparing a control group consuming 20g of proteins (100% of lactoserum proteins) and 650mg of maltodextrin to a test group consuming 20g of proteins (100% of lactoserum proteins) and 650mg of pomegranate extracts after 21 days of supplementation.

Enrollment

30 patients

Sex

All

Ages

65+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Woman and man, aged ≥ 65 years;
BMI from 20 to 30 and from 21 to 30 for a person aged >70 years;
In good general health as evidenced by medical history and physical examination;
Provision of signed and dated informed consent form;
Stated willingness to comply with all study procedures and availability for the duration of the study;
Fluent French speaking.

Exclusion criteria

Severe psychiatric disorder or disease within 6 months before inclusion (depression, bipolar disorder, severe anxiety, psychosis, schizophrenic disorders, dementia...) or severe neurologic trouble (Alzheimer's, autism, Parkinson's disease, ...);
Cancer within less than 3 years before the screening visit (except basal cell skin cancer or squamous cell skin cancer), which in the Investigator's opinion could interfere with the results of the study;
Subjects presenting severe gastro-intestinal, severe hepatic, severe respiratory, severe kidney or severe cardiovascular disorder or severe infection (e.g., HIV, hepatitis, ...);
Uncontrolled hormonal disorders (example: thyroid problems or Cushing's syndrome);
Uncontrolled type 1 or 2 diabetes;
Any clinically significant disease which in the Investigator's opinion could interfere with the safety of study participants or with the results of the study;
Allergy or intolerance to one of the components of the administered products;
Subjects with medications/products incompatible with the study according to the investigator (i.e: medications that could interfere with nutrient absorption);
Subjects having participated in another clinical trial (with an investigational product) one month before the screening;
Mental or legal incapacity, unwillingness or inability to understand or not being able to participate in the study;
Subjects consuming ONS or protein supplements one month before the screening.